印度单日4,205人病殁创新高 穆迪下调现财年GDP增长预测至9.3%
印度疫情持续严峻,据印度卫生部数据,过去24小时新增34.84万宗确诊,累计增至约2,334万宗;单日新增4,205宗死亡病例,创新高,累计25.42万宗。
评级机构穆迪将印度现财年(2022财年)GDP增长预测由13.7%下调至9.3%,并指第二波疫情带来的冲击料较第一波疫情为小;亦料疫情反弹对印度今年次季经济影响有限,下半年经济见强劲反弹。该行排除印度主权评级短期获上调的可能性,并指其自我加剧的经济及金融风险对评级添压。本周较早时间另一评级机构惠誉亦下调印度现财年实际GDP增长预测至9.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.